Short Course versus Standard Course Radiotherapy in Elderly and/or Fragile Patients with Glioblastoma Multiforme (GBM) (E33033)
12 research institutions from 11 Member States have contributed actively to this study: Belarus, Brazil, Canada, Chile, Georgia, Greece, India, Indonesia, Poland, Thailand and Tunisia.
This CRP is about a prospective randomized multi-centre international clinical trial which aimed to establish the optimal shortened radiotherapy (RT) schedule for elderly and/or fragile patients with GBM by comparing overall survival (OS), progression free survival (PFS), and quality of life (QoL) between a one-week RT regimen (Short RT = 25 Gy in 5 daily fractions over one week) with a standard three-week RT regimen (Standard RT = 40 Gy in 15 fractions over three weeks).
More than 100 patients from nine centres were enrolled. The study demonstrated no difference in survival between the two treatment regimens and, at the same time, no increase in toxicity for the shorter fractionated regimen and similar quality of life results between both regimens.
The impact of the study is significant in terms of the possibility of introduction of an effective and resource sparing treatment approach which is convenient for patients and their families, since this subgroup of GBM patients can be treated in a shorter time (one week vs. three weeks) with similar results.
In April 2014 the results of this study were presented at the 33rd Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), the largest and most important event for radiotherapy professionals in Europe, where the group of authors received the Best Clinical Poster Award. Currently a number of manuscripts are in preparation for their publication in professional peer-reviewed journals.
Poster on the results of the study presented during the 33rd Annual Meeting of ESTRO in April 2014.
An example of 3D conformal RT planning for a patient with GBM. Treatment fields are arranged in a way that the prescribed dose is given to the tumour (red), while normal organs (eyes, optical nerves, etc.) are avoided. Treatment is delivered on a modern LINAC with a multileaf collimator (courtesy of Dr D. Guedes de Castro, Brazil).
More Information can be found under following link: